Published online May 16, 2022. doi: 10.12998/wjcc.v10.i14.4669
Peer-review started: January 9, 2022
First decision: February 21, 2022
Revised: March 3, 2022
Accepted: March 27, 2022
Article in press: March 27, 2022
Published online: May 16, 2022
Processing time: 123 Days and 20.4 Hours
PD-1 inhibitors in combination with fruquintinib have not previously been reported as neoadjuvant therapy for patients with colorectal cancer. In this case report, the combination of a PD-1 inhibitor and fruquintinib demonstrated good efficacy in patients with MSI-H colorectal cancer.
The patient was a young man in his 30s who had MSI-H type colon cancer. The patient underwent four cycles of neoadjuvant therapy with a PD-1 inhibitor combined with fruquintinib before surgery, resulting in regression of the mass and a successful surgery.
Some patients with colorectal cancer have the MSI-H type, and the first-line chemotherapy regimen is not effective. However, PD-1 monoclonal antibody immunotherapy has a good therapeutic effect, which can be improved by combination therapy with fruquintinib. We recommend that patients with a history of colon or rectal cancer receive universal MSI testing; then, neoadjuvant therapy should be used.
Core Tip: A 30-year-old man was diagnosed with microsatellite unstable colon cancer. Prior to his surgical treatment, he was treated with a neoadjuvant regimen of PD1 inhibitors in combination with fruquintinib. This neoadjuvant regimen is rarely used; however, this patient had a good outcome. Subsequently, we performed a laparoscopic radical resection of his right colon cancer, which revealed no microscopic tumour cells. The patient was in good condition after the surgical treatment.